Narcolepsy Treatment Market By Type of Disorder (Secondary Narcolepsy, Narcolepsy with cataplexy, Narcolepsy without cataplexy), By Drugs (Amphetamines, Methylphenidate, Modafinil, MAO-B Inhibitors (Selegiline), Tricyclic Anti-Depressants (TCA), Selective Serotonin Reuptake Inhibitors (SSRI), Monoamine Oxidase Type-A (MAO-A) inhibitors), By Distribution Channel (Hospital pharmacies, Retail Pharmacies, Online Pharmacies) and Geography


Purchase Option

$ 3000
$ 4400
$ 6600
$ 8900

Narcolepsy Treatment Market size was valued at USD 3.2 billion in 2021, growing at a CAGR of 9.8% during the forecast period 2022-2028. Narcolepsy is a lifelong sleeping disorder which makes you feel immensely tired sometimes with uncontrollable sudden sleep attacks in severe cases. It is a disabling condition which is characterized by three different symptoms such as excessive daytime cataplexy, sleepiness and irresistible sleep episodes, fluctuating automatic behaviours. Narcolepsy generally begins between 15 to 25 years and it can be evident at any age. Global Narcolepsy Treatment Market is untreated and undiagnosed in many cases. Narcolepsy is the 3rd most common sleeping disorder which affects the large group of the population. A prevalence rate of narcolepsy is substantially lower in Israel i.e. 1 in 500,000 people and considerably high in Japan i.e. 1 in 600 in comparison with U.S. according to the narcolepsy network. Narcolepsy is not curable but can be treated with drugs like dextroamphetamine, methylphenidate etc. to reduce the sleep attacks. Mergers and acquisitions, collaborations, expansions to untapped geographies are the growth strategies that are adopted by the market players to enhance the market growth and to improve their product portfolio. Several voluntary organizations across the world such as Wake up Narcolepsy, Narcolepsy Network, American Sleep Association, and European Narcolepsy Network are actively involving in spreading the awareness regarding the sleeping disorders and their associated symptoms like EDS, sleep paralysis, and cataplexy.

Key Developments:   In January 2017, Jazz pharmaceuticals received U.S.FDA approval for the first generic version of Xyrem to treat narcolepsy patients. In September 2016, Ligand Pharmaceuticals out-licenses 4 development programs to Seelos Therapeutics, that including its H3 receptor antagonist program for narcolepsy, Aplindore program for various CNS disorders, CRTH2 antagonist program for respiratory disorders, Captisol enabled acetaminophen program for fever and pain management.


Global Narcolepsy Treatment Market Summary

Study Period


Base Year




Largest Market


Fastest Growing Market

North America
Narcolepsy Treatment Market Dynamics

Factors that are driving the growth of Global Narcolepsy Treatment Market are growing prevalence of various sleeping disorders including narcolepsy, increase awareness about the sleep disorders. Furthermore, increasing demand for advanced diagnostics and therapeutics to treat sleeping disorders and rise in geriatric population. A narcoleptic disorder is proportionately prevalent to Parkinson’s disease, according to the WHO statistics, more than 3 million people are suffering from narcolepsy across the globe. However, stringent regulatory framework, unawareness about the disorder in underdeveloped countries, abuse usage of the drugs, delayed or undiagnosed of the narcolepsy are the few factors which are hampering the growth of narcolepsy treatment market.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Global Narcolepsy Treatment Market Segmentation

type of disorder
  • Secondary Narcolepsy
  • Narcolepsy with cataplexy
  • Narcolepsy without cataplexy
  • Amphetamines
  • Methylphenidate
  • Modafinil
  • MAO-B Inhibitors (Selegiline)
  • Tricyclic Anti-Depressants (TCA)
  • Selective Serotonin Reuptake Inhibitors (SSRI)
  • Monoamine Oxidase Type-A (MAO-A) inhibitors
Distribution Channel
  • Hospital pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.

[urltag url='request-table-of-content']

  • Arena Pharmaceuticals, Inc.(U.S)
  • Evotec AG (Germany)
  • Graymark Healthcare, Inc. (U.S)
  • Hypnion, Inc. (U.S)
  • Ligand Pharmaceuticals, Inc.(U.S)
  • Teva Pharmaceutical Industries Ltd.(Israel)
  • Jazz Pharmaceuticals, Inc.,(Ireland)